BlackRock, Inc. 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO | BlackRock Inc. BLK | 11,450,079 5.300% | -6,322,666 (-35.58%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | BlackRock Inc. BLK | 17,772,745 8.500% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | BlackRock Inc. BLK | 17,772,745 8.500% | 7,770,941 (+77.70%) | Filing |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | BlackRock Inc. BLK | 10,001,804 5.900% | 1,115,232 (+12.55%) | Filing |
| 2023-02-03 12:09 pm Purchase | 2022-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | BlackRock Inc. BLK | 8,886,572 6.200% | 8,886,572 (New Position) | Filing |